Complications of Sclerotherapy

Seminars in Cutaneous Medicine and Surgery

Volumn 26, Issue 1, 2007, Pages 22-28

  Munavalli, Girish S ^a   Weiss, Robert A ^b,c,d  

^a Dermatology   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Maryland Laser Skin and Vein Institute   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

complications; foam; hyperpigmentation; matting; sclerotherapy; varicose; vein

Indexed keywords

ANTIHISTAMINIC AGENT; GLYCEROL; HYDROQUINONE; POLIDOCANOL; SCLEROSING AGENT; SODIUM CHLORIDE; TETRADECYL SULFATE SODIUM; TRICHLOROACETIC ACID;

ADVERSE OUTCOME; BLOOD VESSEL RUPTURE; HEMOSIDEROSIS; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; INJECTION SITE PAIN; LOW LEVEL LASER THERAPY; NONHUMAN; REVIEW; SCAR FORMATION; SCLEROTHERAPY; SKIN INJURY; SKIN NECROSIS; TELANGIECTASIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; URTICARIA; VARICOSIS; VEIN;

DERMATOLOGY; HUMANS; HYPERPIGMENTATION; NECROSIS; PAIN; SCLEROTHERAPY; TELANGIECTASIS; VARICOSE VEINS;

EID: 33847405627     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2006.12.009     Document Type: Review

References (28)

1. Weiss R.A., Feied C.F., and Weiss M.A. Vein diagnosis and treatment: a comprehensive approach (2001), McGraw-Hill, New York
2. Guex J.J. Contraindications of sclerotherapy, update 2005. J Mal Vasc 30 (2005) 144-149
3. Rabe E., Pannier-Fischer F., Gerlach H., et al. Abstract guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg 30 (2004) 687-693
4. Georgiev M. Postsclerotherapy hyperpigmentations: a one-year follow-up. J Dermatol Surg Onc 16 (1990) 608-610
5. Goldman M.P., Kaplan R.P., and Duffy D.M. Postsclerotherapy hyperpigmentation: A histologic evaluation. J Dermatol Surg Oncol 13 (1987) 547-550
6. Weiss M.A., and Weiss R.A. Efficacy and side effects of 0.1% sodium tetradecyl sulfate in compression scleortherapy of telangiectasias: Comparison to 1% polidocanol and hypertonic saline. J Dermatol Surg Oncol 17 (1991) 90-91
7. Tafazzoli A., Rostan E.F., and Goldman M.P. Q-switched ruby laser treatment for postsclerotherapy hyperpigmentation. Dermatol Surg 26 (2000) 653-656
8. Chatard H. Post-sclerotherapy pigmentation. Phlebol 29 (1976) 211-216
9. Duffy D.M. Small vessel sclerotherapy: An overview. Adv Dermatol 3 (1988) 221-242
10. Weiss R.A., and Weiss M.A. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 16 (1990) 800-804
11. Alderman D.B. Surgery and sclerotherapy in the treatment of varicose veins. Conn Med 39 (1975) 467-471
12. Weiss R.A., and Weiss M.A. Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 16 (1990) 333-336
13. Thibault P.K., and Wlodarczyk J. Correlation of serum ferritin levels and postsclerotherapy pigmentation - a prospective study. J Dermatol Surg Oncol 20 (1994) 684-686
14. McCoy S., Evans A., and Spurrier N. Sclerotherapy for leg telangiectasia-a blinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg 25 (1999) 381-385
15. Leach B.C., and Goldman M.P. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatol Surg 29 (2003) 612-615
16. Norris M.J., Carlin M.C., and Ratz J.L. Treatment of essential telangiectasia: Effects of increasing concentrations of polidocanol. J Am Acad Dermatol 20 (1989) 643-649
17. Weiss R.A., Sadick N.S., Goldman M.P., et al. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 25 (1999) 105-108
18. Duffy D.M. Small vessel sclerotherapy: An overview. Adv Dermatol 3 (1988) 221-242
19. Davis L.T., and Duffy D.M. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity. A retrospective analysis. J Dermatol Surg Oncol 16 (1990) 327-330
20. Barnhill R.L., and Wolfe Jr. J.E. Angiogenesis and the skin. J Am Acad Dermatol 16 (1987) 1226-1229
21. Duffy D.M. Sclerotherapy. In: Alam M., and Nguyen T.H. (Eds). Treatment of leg veins (2006), W.B. Saunders, Philadelphia
22. Breu F.X., and Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany. Dermatol Surg 30 (2004) 709-717
23. Forlee M.V., Grouden M., Moore D.J., et al. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 43 (2006) 162-164
24. Meier B., and Lock J.E. Contemporary management of patent foramen ovale. Circulation 107 (2003) 5-9
25. Bihari I., and Magyar E. Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg 27 (2001) 133-136
26. Shields J.L., and Jansen G.T. Therapy for superficial telangiectasias of the lower extremities. J Dermatol Surg Oncol 8 (1982) 857-860
27. Zimmet S.E. The prevention of cutaneous necrosis following extravasation of hypertonic saline and sodium tetradecyl sulfate. J Dermatol Surg Oncol 19 (1993) 641-646
28. Bergan J., Pascarella L., and Mekenas L.J. Venous disorders: treatment with sclerosant foam. Cardiovasc Surg (Torino) 47 (2006) 9-18